2021 Fiscal Year Final Research Report
Development of a new treatment for HAM/TSP targeting HTLV-1-infected cells
Project/Area Number |
19K07999
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 52020:Neurology-related
|
Research Institution | Kagoshima University |
Principal Investigator |
Kubota Ryuji 鹿児島大学, 総合科学域総合研究学系, 教授 (70336337)
|
Co-Investigator(Kenkyū-buntansha) |
田中 正和 鹿児島大学, 総合科学域総合研究学系, 准教授 (20454613)
松浦 英治 鹿児島大学, 医歯学域医学系, 准教授 (30598800)
|
Project Period (FY) |
2019-04-01 – 2022-03-31
|
Keywords | HTLV-1 / HAM / infected cell |
Outline of Final Research Achievements |
Microarray analysis of CADM1+CD4+HTLV-1 infected cells in peripheral blood lymphocytes (PBMCs) from HTLV-1-associated myelopathy (HAM) patients was performed and identified the differentially expressed genes. We focused on an enzymatic molecule among them, which involved in cellular signaling of CREB. Three inhibitor substances for this enzymatic molecule were added to PBMCs from HAM patients and normal control subjects. We performed a flow cytometric analysis focusing on CADM1+HTLV-1-infected cells and found that, in PBMCs from nine HAM patients, one of the inhibitors showed a significant reduction in infected cells with 20% and 40% in average at 1uM and 5uM, respectively.
|
Free Research Field |
神経免疫学
|
Academic Significance and Societal Importance of the Research Achievements |
HAMではHTLV-1感染細胞が多いことが特徴で、発症及び進行に関与しており、感染細胞を排除することが治療のために重要と考えられている。しかしながら適切な治療法は見つかっていない。本研究ではHTLV-1感染細胞に特異的に発現し、その細胞の生存に重要と思われる分子に注目し、阻害剤の探索を行った。その結果1種類の化合物が試験管内でHAMの感染細胞を特異的に減少させることを見出した。今後さらに確認作業等が必要である。
|